stockportfolio.pro
Stocks / ARWR vs PODD
ARWR vs PODD
Arrowhead Pharmaceuticals, Inc. and Insulet Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Insulet Corporation (PODD) | |
|---|---|---|
| Market cap | $10.0B | $10.3B |
| Revenue (latest FY) | $829.45M | $2.71B |
| Net income (latest FY) | $-1.63M | $247.10M |
| Revenue growth (5y CAGR) | 56.6% | 24.5% |
| Net margin | -0.2% | 9.1% |
| Return on equity | -0.3% | 16.3% |
| P/E ratio | — | 34.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARWR — free Open PODD — freeFrequently asked questions
Which is bigger, ARWR or PODD?
Insulet Corporation is larger by market capitalization — $10.3B versus $10.0B.
Which grows faster, ARWR or PODD?
Over the last five fiscal years, Arrowhead Pharmaceuticals, Inc. grew revenue faster — 56.6%/yr versus 24.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.